Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells

Abstract

In order to identify gene products associated with the development of acquired therapeutic resistance by prostate cancer cells, we created two novel apoptosis-resistant prostate cancer cell lines, LNCaP-TR (phorbol-ester [TPA]-Resistant) and LNCaP-SSR (Serum Starvation-Resistant) by repeated transient exposure of cultured human LNCaP cells to apoptotic stimuli followed by expansion of surviving cell populations. These cell lines were found to be cross-resistant to the alternative selective agent and also hormone-resistant when xenografted into castrated male immunodeficient mice. RNA from the LNCaP-TR line was comparatively screened using a subtractive hybridization-PCR procedure. This allowed us to identify a 249 bp cDNA fragment that hybridized to a 4.8 kb mRNA preferentially expressed by the apoptosis-resistant cells. Using RACE procedures, we cloned and sequenced the complete 4.8 kb cDNA. It is an unusual member of the protocadherin gene family containing two large overlapping open reading frames encoding homologous polypeptides, one having a signal sequence and the other lacking a signal sequence and we refer to it as protocadherin-PC. LNCaP cells directly transformed with protocadherin-PC cDNA were comparatively resistant to phorbol-ester induced apoptosis. Antibody recognition studies demonstrating the cytoplasmic nature of the protcadherin-PC translation product and its propensity to bind β-catenin suggest that it might influence the apoptotic sensitivity of prostate cancer cells through a unique mechanism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Blanco P, Sargent CA, Boucher CA, Mitchell M, Affara NA . 2000 Mammalian Genome 11: 906–914

  • Brothman AR . 1997 Cancer Gen. Cytogenet. 95: 116–121

  • Bucher P, Karplus K, Moeri N, Hoffman K . 1996 Computers Chem. 20: 3–24

  • Buttyan R, Zakeri Z, Lockshin R, Wolgemuth D . 1988 Mol. Endocrin. 2: 650–657

  • Cheshire DR, Ewing CM, Gage WR, Isaacs WB . 2002 Oncogene 21: 2679–2694

  • Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ . 1979 Biochem. 18: 5294–5299

  • Craft N, Shostak Y, Carey M, Sawyers CL . 1999 Nature Med. 5: 264–265

  • Dasari VK, Goharderakhshan RZ, Perindchery G, Li LC, Tanaka Y, Alonzo J, Dahiya R . 2001 J. Urol. 165: 1335–1341

  • Diatchenko L, Lau Y-FC, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukayanov S, Lukayanov K, Gurskaya N, Sverdlov ED, Siebert PD . 1996 Proc. Natl. Acad. Sci., U.S.A. 93: 6025–6030

  • Dignam JD, Lebovitz RM, Roeder RG . 1983 Nucleic Acids Res. 11: 1475–1489

  • Eddy S . 1998 HMMER User's Guide: Biological Sequence Analysis Using Profile Hidden Markov Models, Version 2.1, 1-70 St. Louis: Dept. of Genetics, Washington University School of Medicine

    Google Scholar 

  • Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT . 1996 Clin. Cancer Res. 2: 389–398

  • Grossman ME, Huang H, Tindall DJ . 2001 J. Natl. Cancer Inst. 93: 1687–1697

  • Hoffman K, Bucher P, Falquet L, Bairoch A . 1999 Nucleic Acids Res. 27: 215–219

  • Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA . 1980 Prog. Clin. Biol. Res. 37: 115–132

  • Hsiao PW, Chang C . 1999 J. Biol. Chem. 274: 22373–22379

  • Huggins C, Hodges CV . 1941 Cancer Res. 1: 293–298

  • Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF, Batra SK . 2001 Clin. Cancer Res 7: 3472–3480

  • Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC . 1996 Am. J. Pathol. 146: 1567–1576

  • Lau YF, Zhang J . 2000 Mol. Carcinogen. 27: 308–321

  • Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ . 2000 Cancer Res. 60: 944–949

  • McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ . 1997 J. Urol. 157: 569–574

  • Murphy GP, Slack NH . 1980 Urol. Clin. North Am. 7: 631–638

  • Nielsen H, Engelbrecht J, Brunak S, von Heijne G . 1997 Protein Engineering 10: 1–6

  • Pearson WR . 1996 Methods in Enzymology 266 Doolittle RF (ed) San Diego: Academic Press pp 227–258

    Google Scholar 

  • Raffo AR, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R . 1995 Cancer Res. 55: 4438–4445

  • Reese MG, Harris NL, Eeckman FH . 1996 Large scale sequencing specific neural networks for promotor and splice site recognition Hunter L and Klein TE (eds) Proceedings of the 1996 Pacific Symposium World Scientific Publishing Co., Singapore, 1996 pp 2–7

    Google Scholar 

  • Resnick MI, Grayhack JT . 1975 Urol. Clin. North Am. 2: 141–161

  • Rost B, Casadio R, Fariselli P, Sander C . 1995 Protein Science 4: 521–533

  • Rost B, Fariselli P, Casadio R . 1996 Protein Science 7: 1704–1718

  • Shen R, Dorai T, Szabolcs M, Katz AE, Olsson CA, Buttyan R . 1997 Urol. Oncol. 3: 67–75

  • Smith TF, Waterman MS . 1981 J. Mol. Biol. 146: 195–197

  • Sonnhammer EL, Eddy SR, Durbin R . 1997 Proteins 28: 405–420

  • Stappert J, Kemler R . 1994 Cell Adhes. Commun. 2: 319–327

  • Suzuki ST . 1996 J. Cell Biochem. 61: 531–542

  • Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstra EJ, Lieber MM, Jenkins RB . 1996 Clin. Cancer. Res. 2: 137–145

  • Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP . 1995 N.E.J.M. 332: 1393–1398

  • Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP . 1999 Cancer Res. 59: 2511–2515

  • Tricoli JV . 1999 Cancer Gen. Cytogenet. 111: 1–6

  • van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J . 1991 Int. J. Cancer 48: 189–193

  • Whang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C . 2001 J. Biol. Chem. 276: 40417–40423

  • Wooton JC, Federhen S . 1996 Methods in Enzymology 266: Doolittle RF (ed) San Diego, CA: Academic Press pp 554–571

    Google Scholar 

  • Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C . 1999 Proc. Natl. Acad. Sci. U.S.A. 96: 5458–5463

  • Yoshida K, Sugano S . 1999 Genomics 62: 540–543

  • Zhang X, Colombel M, Raffo A, Buttyan R . 1994 Biochem. Biophys. Res. Commun. 198: 1189–1194

Download references

Acknowledgements

This work was supported by funding from US Department of Defense (DAMD-PC970137 and PC001565) and The TJ Martell Foundation for AIDS and Cancer Research, NY (to R Buttyan) and by l'Association de Recherche Contre le Cancer (ARC), le Comite des Hauts de Seine de la ligue centre le Cancer (to DK Chopin). Alexandre de la Taille was supported by a Fellowship from the French Urological Association–ARTP (France) and Francis Vacherot by a generous grant from Debat-Fournier, Inc. (France).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ralph Buttyan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, MW., Vacherot, F., de la Taille, A. et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 21, 7861–7871 (2002). https://doi.org/10.1038/sj.onc.1205991

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205991

Keywords

This article is cited by

Search

Quick links